Pharminent

Novartis exercises option with Conatus for NASH treatment

Novartis has exercised its option with ConatusPharmaceuticals for an exclusive license for the worldwide development and commercialization of emricasan, a potential treatment for non-alcoholic steatohepatitis (NASH). http://drugdiscovery.pharmaceutical-business-review.com/news/novartis-exercises-option-to-develop-conatus-emricasan-to-treat-nash-050517-5805546

Filed under: Company